Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Trilaciclib by G1 Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Trilaciclib is under clinical development by G1 Therapeutics and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According to...
Data Insights
Trilaciclib by G1 Therapeutics for Bladder Cancer: Likelihood of Approval
Trilaciclib is under clinical development by G1 Therapeutics and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...